Tacrolimus · oral capsule
Misc.
Approved uses
Prophylaxis of organ rejection in liver, kidney, heart or lung transplantation
Dosed by body weight and adjusted to whole-blood trough concentration, given consistently with or without food
PRES is the ocular emergency to know: visual disturbance up to cortical blindness
OFF-LABELNot in the FDA label for this product
Non-infectious uveitis, as a corticosteroid-sparing agent
Oral, titrated to effect and to renal tolerance
Cohort · n=62 · steroid taper
A retrospective series of 62 consecutive patients with non-infectious uveitis treated with tacrolimus found they tapered oral prednisone to 10 mg daily at a rate of 1.62 per patient-year, with an 85% probability of reaching 10 mg or less after about 14 months. Tacrolimus was stopped for intolerance at 0.13 per patient-year, and the cardiovascular measures that limit other agents stayed low: new or increased treatment for hypertension, cholesterol or diabetes each ran below 0.05 per patient-year, and creatinine rises of 30% or more were uncommon at 0.05 per patient-year.
Contraindications
- Hypersensitivity to tacrolimus
- Hypersensitivity to HCO-60 (polyoxyl 60 hydrogenated castor oil), for the injection
0.5 mg, 1 mg, 5 mg capsules (100 count bottle), 5 mg/mL injection (1 mL ampules, 10 per box), 0.2 mg, 1 mg granules (50 packets)
Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT), and nuclear factor kappa-light-chain enhancer of activated B-cells (NF-κB).
Warnings & Precautions
- Malignancies and serious infections: immunosuppressants, including PROGRAF, raise the risk of serious infections and of lymphoma and other malignancies, particularly of the skin, and these may lead to hospitalization or death. This carries a boxed warning.
- Lymphoma and other malignancies: examine patients for skin changes, and limit exposure to sunlight and UV light with protective clothing and a broad-spectrum sunscreen with a high protection factor. Post-transplant lymphoproliferative disorder (PTLD) has been reported, and most PTLD events appear related to Epstein-Barr Virus (EBV) infection. The risk of PTLD appears greatest in EBV seronegative patients, a group that includes many young children. Monitor EBV serology during treatment.
- Serious infections: patients are at increased risk of bacterial, viral, fungal and protozoal infections, including opportunistic infections, which may lead to serious, including fatal, outcomes. Serious viral infections reported include polyomavirus-associated nephropathy (mostly due to BK virus), JC virus-associated progressive multifocal leukoencephalopathy (PML) and cytomegalovirus infections. Monitor for infection and adjust the immunosuppressive regimen to balance rejection risk against infection risk.
- Nephrotoxicity: tacrolimus can cause acute or chronic nephrotoxicity. The risk may increase with CYP3A inhibitors, which raise tacrolimus blood concentrations, and with other drugs associated with nephrotoxicity, such as aminoglycosides, amphotericin B or cisplatin. With these nephrotoxic drugs, monitor renal function and tacrolimus blood concentrations and adjust doses. Consider a dosage reduction or temporary interruption when serum creatinine is elevated and troughs exceed the recommended range.
- Neurotoxicity: tacrolimus may cause neurotoxicity, most severely posterior reversible encephalopathy syndrome, delirium, seizure and coma, and also tremor, paresthesia, headache, mental status changes and changes in motor and sensory functions. Symptoms may be associated with whole blood trough concentrations at or above the recommended range. Monitor for neurologic symptoms, and consider a lower dose or stopping if neurotoxicity occurs.
- Blindness and optic neuropathy: blindness, optic neuropathy, cortical blindness and photophobia have been reported in postmarketing experience with tacrolimus.
- Hypertension and hyperkalemia: hypertension is a common adverse effect and may need antihypertensive treatment. Hyperkalemia has been reported, so monitor serum potassium periodically. Give careful consideration before using other agents also associated with hyperkalemia, such as potassium-sparing diuretics, ACE inhibitors and angiotensin receptor blockers. Calcium-channel blocking agents may increase tacrolimus blood concentrations and require a lower PROGRAF dose.
- New-onset diabetes after transplant: tacrolimus was shown to cause new-onset diabetes in transplant trials, and the diabetes may be reversible in some patients. African-American and Hispanic kidney transplant patients are at an increased risk. Monitor blood glucose closely.
- QT prolongation: tacrolimus may prolong the QT/QTc interval and may cause torsades de pointes; avoid it in congenital long QT syndrome. In patients with congestive heart failure, bradyarrhythmias or electrolyte disturbances such as hypokalemia, hypocalcemia or hypomagnesemia, and in those taking certain antiarrhythmic medications or other drugs that lead to QT prolongation, consider obtaining electrocardiograms and monitoring electrolytes periodically.
- Toxicity and efficacy failure: the relative risks of toxicity and efficacy failure are related to tacrolimus whole blood trough concentrations, so therapeutic drug monitoring is recommended for all patients receiving tacrolimus.
- Interactions with CYP3A4 inhibitors and inducers: with strong CYP3A4 inhibitors, such as ritonavir, ketoconazole, itraconazole, voriconazole or clarithromycin, or strong inducers, such as rifampin or rifabutin, tacrolimus dose adjustment and frequent monitoring of whole blood trough concentrations and adverse reactions are recommended. A rapid, sharp rise in tacrolimus levels has been reported with clarithromycin despite an initial dose reduction.
- Medication errors: PROGRAF is not interchangeable or substitutable with extended-release tacrolimus products. Substitution and dispensing errors between immediate-release and extended-release tacrolimus, reported outside the U.S., led to serious adverse reactions, including graft rejection. Changes between these forms must occur under physician supervision. Teach patients and caregivers to recognize PROGRAF dosage forms and to check with the provider if a different product is dispensed.
- Interference with immunization: tacrolimus can interfere with the usual response to immunizations. Avoid live vaccines during treatment; examples include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines. Whenever possible, give the complete set of vaccines before transplantation and treatment. Inactivated vaccines may not be sufficiently immunogenic during treatment.
- Anaphylactic reactions: anaphylactic reactions have occurred with injectables containing castor oil derivatives, including PROGRAF, in 0.6% of patients. Reserve the injection for patients unable to take PROGRAF orally, and monitor for anaphylaxis with intravenous use.
- Excess mortality and graft loss: PROGRAF is not recommended with sirolimus. In de novo liver transplant studies the combination was associated with excess mortality, graft loss and hepatic artery thrombosis. In a U.S. heart transplant trial, sirolimus 2 mg per day with PROGRAF was associated with an increased risk of renal function impairment, wound healing complications and insulin-dependent post-transplant diabetes, and the combination may increase the risk of thrombotic microangiopathy.
- Myocardial hypertrophy: myocardial hypertrophy has been reported in infants, children and adults, particularly with high tacrolimus trough concentrations, and appears reversible in most cases after dose reduction or stopping therapy. Consider echocardiography if renal failure or clinical signs of ventricular dysfunction develop, and consider a lower dose or stopping PROGRAF if myocardial hypertrophy is diagnosed.
- Pure red cell aplasia: cases have been reported with tacrolimus, and all patients had risk factors such as parvovirus B19 infection, underlying disease or concomitant drugs associated with it. Consider stopping PROGRAF if it is diagnosed.
- Thrombotic microangiopathy: TMA, including hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, has been reported with PROGRAF. Transplant risk factors include severe infection, graft-versus-host disease, HLA mismatch and the use of calcineurin and mTOR inhibitors, so consider tacrolimus as a risk factor in a patient with signs of TMA.
- Tacrolimus toxicity: cannabidiol may raise tacrolimus blood levels. When the two are given together, closely monitor tacrolimus blood levels and watch for adverse reactions that suggest tacrolimus toxicity, and consider a lower PROGRAF dose as needed.
Common Side Effects
The most common adverse reactions (≥ 15%) were abnormal renal function, hypertension, diabetes mellitus, fever, CMV infection, tremor, hyperglycemia, leukopenia, infection, anemia, bronchitis, pericardial effusion, urinary tract infection, constipation, diarrhea, headache, abdominal pain, insomnia, paresthesia, peripheral edema, nausea, hyperkalemia, hypomagnesemia, and hyperlipemia.
Pregnancy: tacrolimus can cause fetal harm. Postmarketing and registry data suggest that infants exposed in utero are at risk of prematurity, birth defects, low birth weight and fetal distress, and renal dysfunction and transient neonatal hyperkalemia have been reported at delivery. PROGRAF may increase hyperglycemia in pregnant women with diabetes, including gestational diabetes, and may exacerbate hypertension and increase pre-eclampsia. Monitor maternal blood glucose levels regularly, and monitor and control blood pressure.
Lactation: tacrolimus has been reported in human milk; weigh the benefits of breastfeeding against the mother's clinical need for PROGRAF and any potential effect on the infant.
Safety and effectiveness have been established in pediatric liver, kidney, heart, and lung transplant patients.